Thus, abrogated IDH activity is a target for treatment of R/R IDH-mutated AML, with three FDA-approved IDH inhibitors: ivosidenib (AG-120, IDH1 inhibitor), olutasidenib (FT-2102, IDH1 inhibitor), and enasidenib (AG-221, IDH2 inhibitor) [52, 94-102]. Here, IDH2 is linked to acute myeloid leukemia.